Tretinoin: A Review of Its Anti-inflammatory Properties in the Treatment of Acne.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 3225141)

Published in J Clin Aesthet Dermatol on November 01, 2011

Authors

Nicholas Schmidt1, Eugene H Gans

Author Affiliations

1: Medicis Pharmaceutical Corporation, Scottsdale, Arizona.

Articles cited by this

Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol (1989) 2.77

Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62

The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) (2003) 2.49

New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol (2009) 2.16

Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol (2002) 2.14

Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect (2006) 1.91

The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses. J Invest Dermatol (1990) 1.83

Inflammatory events are involved in acne lesion initiation. J Invest Dermatol (2003) 1.83

Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol (2005) 1.76

Cytokine modulation of keratinocyte cytokines. J Invest Dermatol (1990) 1.59

Evidence for an epidermal cytokine network. J Invest Dermatol (1990) 1.48

IFN-gamma regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro. J Immunol (1990) 1.38

Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol (1986) 1.38

Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol (2004) 1.37

Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun (1995) 1.37

Immunomodulating effects of antibiotics: literature review. Infection (1997) 1.35

Acne vulgaris. Lancet (1998) 1.25

Complement activation in acne vulgaris: in vitro studies with Propionibacterium acnes and Propionibacterium granulosum. Infect Immun (1978) 1.16

Pathogenesis of acne. Med Electron Microsc (2001) 1.15

Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol (2005) 1.15

Inflammation in acne vulgaris. J Am Acad Dermatol (1995) 1.15

Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation (1980) 1.14

Enzymatic and hemolytic properties of Propionibacterium acnes and related bacteria. J Clin Microbiol (1977) 1.14

The chemoattractant properties of comedonal components. J Invest Dermatol (1978) 1.10

The production of hyaluronidase (hyaluronate lyase) by Corynebacterium acnes. J Invest Dermatol (1972) 1.07

Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol (1992) 1.06

A histological and immunocytochemical study of early acne lesions. Br J Dermatol (1988) 1.05

Ultraviolet B injury increases prostaglandin synthesis through a tyrosine kinase-dependent pathway. Evidence for UVB-induced epidermal growth factor receptor activation. J Biol Chem (1994) 1.02

Acne: a review of immunologic and microbiologic factors. Postgrad Med J (1999) 1.01

Purification and partial characterization of an acid phosphatase (EC 3.1.3.2) produced by Propionibacterium acnes. J Gen Microbiol (1980) 1.01

Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris. J Invest Dermatol (2003) 1.00

The role of innate immunity in the pathogenesis of acne. Dermatology (2003) 0.98

Propionibacterium acnes stimulates pro-matrix metalloproteinase-2 expression through tumor necrosis factor-alpha in human dermal fibroblasts. J Invest Dermatol (2007) 0.98

Topical clindamycin treatment of acne. Clinical, surface lipid composition, and quantitative surface microbiology response. Arch Dermatol (1980) 0.97

Update and future of systemic acne treatment. Dermatology (2003) 0.96

Polymorphonuclear leukocyte lysosomal release in response to Propionibacterium acnes in vitro and its enhancement by sera from inflammatory acne patients. J Invest Dermatol (1980) 0.96

Antibody response to crude cell lysate of propionibacterium acnes and induction of pro-inflammatory cytokines in patients with acne and normal healthy subjects. J Microbiol (2004) 0.96

The treatment of acne: the role of combination therapies. J Am Acad Dermatol (1995) 0.94

A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis (2010) 0.93

Cytotaxin production by comedonal bacteria (Propionibacterium acnes, Propionibacterium granulosum and Staphylococcus epidermidis). J Invest Dermatol (1980) 0.93

Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells. Br J Pharmacol (2000) 0.93

The effects of retinoids on neutrophil functions in vitro. J Am Acad Dermatol (1982) 0.92

Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol (1981) 0.91

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol (2005) 0.90

The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol (2003) 0.90

Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition. Infect Immun (1982) 0.90

Heat shock proteins and inflammatory acne vulgaris: molecular cloning, overexpression and purification of a propionibacterium acnes GroEL and DnaK homologue. FEMS Microbiol Lett (2000) 0.90

Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol (2005) 0.90

Topical antibacterial therapy for acne vulgaris. Drugs (2004) 0.90

Propionibacterium acnes-induced IL-8 production may be mediated by NF-kappaB activation in human monocytes. J Dermatol Sci (2002) 0.89

Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol (2002) 0.89

Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther (2002) 0.89

Complement activation by Corynebacterium acnes. Br J Dermatol (1978) 0.89

Pathogenesis and pathogenesis related treatment of acne. J Dermatol (1991) 0.88

The sebaceous gland and acne--40 years on. Dermatology (1998) 0.88

Pharmacology and chemistry of adapalene. J Am Acad Dermatol (1997) 0.88

Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol (2003) 0.87

A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol (2000) 0.87

Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest (1997) 0.86

The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions (1990) 0.86

Topical antibacterial treatments for acne vulgaris : comparative review and guide to selection. Am J Clin Dermatol (2004) 0.86

Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother (2001) 0.86

Mechanism of anti-inflammatory action of retinoids on keratinocytes. Lancet (1994) 0.85

Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother (1982) 0.84

Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol (2001) 0.84

Retinoids inhibit the respiratory burst and degranulation of stimulated human polymorphonuclear leukocytes. Agents Actions (1991) 0.83

Propionibacterium acnes and acne. Dermatology (1998) 0.83

Suppressive effects of linoleic acid on neutrophil oxygen metabolism and phagocytosis. J Invest Dermatol (1990) 0.83

In vitro modulation of epidermal inflammatory cytokines (IL-1 alpha, IL-6, TNF alpha) by minocycline. Arch Dermatol Res (1996) 0.82

An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther (1993) 0.82

All-trans retinoic acid shifts Propionibacterium acnes-induced matrix degradation expression profile toward matrix preservation in human monocytes. J Invest Dermatol (2008) 0.82

Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci (2005) 0.82

CD23-mediated nitric oxide synthase pathway induction in human keratinocytes is inhibited by retinoic acid derivatives. J Invest Dermatol (1996) 0.81

Effects of retinoids on macrophage function and IL-1 activity. J Leukoc Biol (1988) 0.81

Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro. Eur J Pharmacol (1984) 0.81

Anti-inflammatory effect of retinoic acid on prostaglandin synthesis in cultured cortical astrocytes. J Neurochem (2008) 0.81

Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol (1998) 0.80

Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol (2005) 0.80

Topical retinoids in acne--an evidence-based overview. J Dtsch Dermatol Ges (2008) 0.79

Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody. Int J Dermatol (1999) 0.79

Effects of all-trans retinoic acid on neutrophil-mediated endothelial cell injury in vitro and immune complex injury in rats. Am J Pathol (1991) 0.78

Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol (1983) 0.77

Anti-inflammatory effects of tretinoin (all-trans-retinoic acid) 0.1% and adapalene 0.1% in rats. Clin Exp Dermatol (2005) 0.77

Immunomodulatory effects of tretinoin in combination with clindamycin. J Eur Acad Dermatol Venereol (1998) 0.77

A method for the assay of inflammatory mediators in follicular casts. J Invest Dermatol (1979) 0.76

Inhibition of neutrophil chemotactic factor production in comedonal bacteria by subminimal inhibitory concentrations of erythromycin. Dermatology (1992) 0.75

The potential immunomodulatory effects of topical retinoids. Dermatol Online J (2005) 0.75